Azitra, INC 10-K annual reports

Azitra, Inc. reported increased net losses and a significant accumulated deficit for 2025, raising substantial doubt about its ability to continue as a going concern, despite progress in early-stage clinical trials and recent capital raises.

Azitra, Inc.'s 10-K filing summarizes the company's financial results for fiscal year 2024 and provides an update on its clinical development programs in precision dermatology.

Azitra, Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Azitra Inc.'s 10-K filing details the company's capital structure, ongoing clinical programs, and strategic focus on precision dermatology.